- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05251792
Macular Pigment Optical Density in Primary Angle-closure Disease
February 9, 2023 updated by: Zhongshan Ophthalmic Center, Sun Yat-sen University
Study on the Relationship Between Macular Pigment Optical Density and Primary Angle-closure Disease
Glaucoma is the leading cause of irreversible blindness in the world, and primary angle-closure glaucoma (PACG) is the most important type of glaucoma in Asia.
Primary angle closure disease (PACD) is a group of diseases related to PACG, and the pathogenesis is still unclear.
Macular pigment has the functions of filtering short-wavelength waves and anti-oxidation, which are related to visual function.
Previous studies have found that the macular pigment density (MPOD) is significantly reduced in primary open-angle glaucoma.
This project uses the single-wavelength reflection method to measure MPOD, observes the characteristics of PACD and the normal control group's changes in retinal MPOD, and explains the relationship between PACD's MPOD changes and angle-closure glaucoma optic nerve damage
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Observation index: Visual acuity,Intraocular pressure,Ophthalmoscope,MPOD,Visual field and OCT.
Inspection parameters of OCT:
- Retinal nerve fiber layer thickness
- Ganglion cell complex thickness
- Mean thickness of the central retina
- Mean defect
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhihong Huang, M.D
- Phone Number: 02066615461 +8602066615461
- Email: 575772588@qq.com
Study Contact Backup
- Name: Chengguo Zuo, M.D,Ph.D
- Phone Number: 02066615461 +8602066615461
- Email: chengguozuo@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Zhognshan Ophthalmic Center, Sun Yat-sen University
-
Contact:
- Zhihong O Huang
- Phone Number: 02066615461 +8602066615461
- Email: 575772588@qq.com
-
Contact:
- Chengguo O Zuo
- Phone Number: 02066615461 +8602066615461
- Email: chengguozuo@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Outpatients >=40 years old PACD
Description
Inclusion Criteria:
- Experimental group:
- (1) According to the diagnostic criteria of PACD
- (2)History of peripheral iridectomy or trabeculectomy
- (3)Over 40
- (4)Phakic eyes
- (5)Intraocular pressure is less than 21mmhg, more than one week
- (6)Eyes with clear optical media.
- Control group:
- (1)No history of glaucoma and other eye diseases
- (2)Phakic eyes
- (3)Over 40
- (4)Intraocular pressure10~21mmHg
Exclusion Criteria:
- (1)History of corneal diseases
- (2)History of eye tumor or other ophthalmic surgery
- (3)Cataract
- (4)Taking supplements containing lutein within 6 months
- (5)Snellen's visual acuity was less than 6 / 20,the diopter is beyond ± 6 degrees
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Primary Angle Clousure Diseases Eyes
Over 40 years old, regardless of gender.
Patients diagnosed with PACD (PACG or PAC or PACS) with phakic eyes.
Peripheral iridectomy or trabeculectomy, more than 3 months after operation.
|
All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
|
Matched Eyes
Healthy population matched by sex and age.
|
All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Macular Pigment Optical Density(MPOD)Measurement
Time Frame: 3 months after surgery
|
A one-wavelength fundus reflectance method (Visucam 200; Carl Zeiss Meditec) was used for the detection of MPOD as previously described.
The right or left eye was randomly selected for measurement.
The parameters and profiles of MPOD in a 7-degree eccentricity that corresponded to a 4 mm diameter were evaluated and output.
Parameters included max and mean optical density (OD), volume, and area.
MaxOD and MeanOD with units "d.u." (initial of density units) were used for the analyses.
|
3 months after surgery
|
Retinal nerve fiber layer thickness
Time Frame: 3 months after surgery
|
Detection by optical coherence tomography (OCT).
Circumpapillary RNFL scans were obtained using the standard 3.4 mm 12-degree circumpapillary nerve fiber layer scan protocol.We recorded superior, inferior, nasal, temporal, and total RNFL thickness.
|
3 months after surgery
|
Ganglion cell complex (GCC)thickness
Time Frame: 3 months after surgery
|
Detection by optical coherence tomography (OCT).
The distance from the internal limiting membrane and outer edge of the outer plexiform layer was defined as GCC thickness.
|
3 months after surgery
|
Mean central retina thickness
Time Frame: 3 months after surgery
|
Detection by optical coherence tomography (OCT).
CRT thickness was defined as distance between the internal limiting membrane and the inner edge of the retinal pigment epithelium.
|
3 months after surgery
|
Mean outer retinal thickness
Time Frame: 3 months after surgery
|
Outer retinal (OR) thickness was calculated by subtracting GCC thickness from CRT.
|
3 months after surgery
|
Visual Field Test
Time Frame: 3 months after surgery
|
The visual field test uses the 30-2 Threshold Test on the Humphrey Visual Field Analyzer.According to the mean deviation (MD) values generated by the software, three groups of disease severity were classified: the mild group with MD > -6 dB, the moderate group with MD between -6 and -12 dB, and the severe group with MD < -12 dB
|
3 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual acuity
Time Frame: 3 months after surgery
|
Use Snellen visual acuity chart to measure naked eye vision and best corrected vision
|
3 months after surgery
|
Intraocular pressure
Time Frame: 3 months after surgery
|
Using non-contact tonometer (NCT) measuring intraocular pressure
|
3 months after surgery
|
Cup/ Disk ( C/ D)
Time Frame: 3 months after surgery
|
determine the cup to disc ratio by ophthalmoscope
|
3 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Chengguo Zuo, Zhognshan Ophthalmic Center, Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 11, 2021
Primary Completion (ANTICIPATED)
March 30, 2024
Study Completion (ANTICIPATED)
December 30, 2024
Study Registration Dates
First Submitted
February 11, 2022
First Submitted That Met QC Criteria
February 11, 2022
First Posted (ACTUAL)
February 23, 2022
Study Record Updates
Last Update Posted (ACTUAL)
February 13, 2023
Last Update Submitted That Met QC Criteria
February 9, 2023
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020KYPJ82
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data (IPD) needed to be keep security.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico
Clinical Trials on Ocular examination
-
Medical University of ViennaRecruiting
-
Nantes University HospitalTerminated
-
Insel Gruppe AG, University Hospital BernStiftung OPOS; Fondation BertarelliRecruiting
-
Alcon ResearchCompletedDry Eye DiseaseAustralia
-
First Affiliated Hospital of Harbin Medical UniversityUnknown
-
First Affiliated Hospital of Harbin Medical UniversityUnknown
-
First Affiliated Hospital of Harbin Medical UniversityUnknown
-
Brighton and Sussex University Hospitals NHS TrustCompletedAge Related Macular Degeneration | Cataract Senile | Epiretinal Membrane | Vitreomacular Traction | Macula HoleUnited Kingdom
-
Glostrup University Hospital, CopenhagenCompleted
-
Cleveland Clinic Akron GeneralRecruiting